What is Tirzepatide?
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist — the first-in-class twincretin. Acts simultaneously on GIPR and GLP-1R to produce synergistic effects on insulin secretion, glucagon suppression, gastric emptying, and appetite suppression. Phase 3 (SURMOUNT-1): 20.9% mean weight loss at 72 weeks (15mg). The 120mg vial format provides high total peptide loading per kit for extended research protocols. Research use only.
Research Applications
Dual GIP/GLP-1 Receptor Agonism
Simultaneous GIPR + GLP-1R activation — synergistic vs individual receptor pharmacology
Incretin Axis Research
GIP/GLP-1 co-signalling, cAMP pathway, beta-cell insulin secretion and glucagon suppression
Metabolic & Weight Research
SURMOUNT-1 reference compound — 20.9% mean weight loss at 72 weeks
Glucose Homeostasis
Postprandial glucose excursion, hepatic glucose output, peripheral insulin sensitivity
Twincretin vs Monoagonist
Tirzepatide vs GLP-1R-only agonists — additive/synergistic metabolic outcomes comparison
Quick Specs
| Form | Lyophilized powder |
| Purity | ≥99% by HPLC — every batch |
| CAS Number | 2023788-19-2 |
| Molecular Formula | C₂₂₅H₃₄₈N₄₈O⁸, MW ~4814 Da |
| Peptide Type | Dual GIP/GLP-1 Receptor Agonist (Twincretin) |
| Identity | MS molecular weight confirmed — every batch |
| COA | Janoshik-independent, publicly verifiable |
| Manufacture | In-house Fmoc SPPS — Qingdao, China |
| Storage | −20°C sealed | 2–8°C reconstituted (2–4 weeks) |
| Shelf Life | 24 months (unopened) |

